Bigfoot Biomedical Announces Insulin Compatibility Expansion to Support Insulin Affordability and Flexibility for People with Diabetes


MILPITAS, Calif.–(BUSINESS WIRE)–Bigfoot Biomedical, a mission-driven company dedicated to supporting better health outcomes for people with insulin-requiring diabetes, today announced its Bigfoot Unity® Diabetes Management System is now compatible with four additional rapid-acting insulin products, including two unbranded biologics. All four insulin products are offered at a reduced price without compromising on quality, helping to expand insulin access for people with diabetes.1

“Bigfoot recognizes the urgent need to provide millions of Americans with affordable access to diabetes care. It’s a critical part of our mission,” said Jeffrey Brewer, CEO of Bigfoot Biomedical. “Our expansion of compatibility to include additional insulin brands will make it easier for Bigfoot to support a broader population of people with diabetes requiring insulin and will give Bigfoot Unity users greater flexibility to switch from brand of insulin to another when they change insurance. This news marks an important moment in time for Bigfoot as we work to make insulin-based diabetes management tools more accessible to people who need them.

The Bigfoot Unity System, the first and only FDA-cleared dose decision support system based on CGM data for people using multiple daily injections, includes smart pen caps that are compatible with a wide range of disposable insulins for long-acting and rapid-acting insulin. . From now on, the system will also be compatible with the following:

  • Eli Lilly’s (LLY:NYSE) Insulin Lispro, an unbranded biologic that is the same molecule as Humalog®

  • Insulin Aspart from Novo Nordisk (NVO:NYSE), an unbranded biologic that is the same molecule as Novolog®

  • ReliON Novo Log® insulin, a private-label insulin analogue manufactured by Novo Nordisk and available exclusively at Walmart and Sam’s Club pharmacies; ReliOn is the same molecule as Novolog

The above insulins are available at a list price at least 50% lower than their brand name equivalent.2

The Bigfoot Unity system is also now compatible with Eli Lilly’s Lyumjev® (insulin injection lispro-aabc), a new rapid-acting insulin from Lilly that is included in Lilly’s Insulin Value Program, allowing anyone with commercial insurance and those without insurance to fill their prescription monthly from Lyumjev for $35.

The decision to offer low-cost insulin products as a compatible option with the Bigfoot Unity System is just one step the company has taken to expand access for people with diabetes who require insulin. The company is also taking steps to make its insulin management technology more widely available to people in rural communities and working to improve access for Medicare and Medicaid populations.

About Bigfoot Biomedical, Inc.

Bigfoot Biomedical was founded by a team of people with personal ties to type 1 and type 2 diabetes. We seek to change the paradigm of diabetes care. Bigfoot is an unconventional company taking an unconventional approach. Unlike others, we view insulin therapy holistically and utilize services, support and new business models. We partner with healthcare professionals to provide simple, connected and comprehensive solutions for the vast number of people who have been overlooked by diabetes innovation. Learn more on our website and by following us on LinkedIn, TwitterInstagram and Facebook.

1 Insulin is now a biologic – what does that mean?American Diabetes Association,

2 Data archived by Bigfoot Biomedical

All product and company names are registered trademarksor registered® trademarks of their respective owners. Their use does not imply any affiliation with or endorsement by them.


About Author

Comments are closed.